News

Aarti Industries announced that the Board of Directors of the Company at its meeting held on 4 May 2026, inter alia, have recommended the final dividend of Rs 1 per equity Share (i.e. 20%) , subject to the approval of the shareholders.

Net profit of Aarti Industries rose 42.71% to Rs 137.00 crore in the quarter ended March 2026 as against Rs 96.00 crore during the previous quarter ended March 2025. Sales rose 13.13% to Rs 2205.00 crore in the quarter ended March 2026 as against Rs 1949.00 crore during the previous quarter ended March 2025.For the full year,net profit rose 26.97% to Rs 419.00 crore in the year ended March 2026 as against Rs 330.00 crore during the previous year ended March 2025. Sales rose 13.99% to Rs 8286.00 crore in the year ended March 2026 as against Rs 7269.00 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales2205.001949.00 13 8286.007269.00 14 OPM %15.4613.44 -14.0813.70 - PBDT230.00201.00 14 832.00739.00 13 PBT111.0088.00 26 358.00305.00 17 NP137.0096.00 43 419.00330.00 27 Powered by Capital Market - Live News

Aarti Industries will hold a meeting of the Board of Directors of the Company on 4 May 2026.

Aarti Industries has allotted 122 equity shares under ESOP on 13 April 2026. With this allotment, the paid up equity share capital has increased to Rs. 1,81,29,72,455 /- (divided in to 36,25,94,491 equity shares of Rs. 5/- each).

Aarti Industries has entered into a multi-year supply agreement with a top global agrochemical innovator for the supply of a critical agrochemical intermediate used in crop protection formulations. This agreement elevates the current annual engagement to a structured supply contract through 31st March 2030, with a significant increase in volumes. The agreement is expected to generate revenue of approximately USD 150 million over the contract period, providing AIL with enhanced revenue visibility in the medium to long term. Under the terms of the agreement, AIL will manufacture and supply the intermediate, leveraging its integrated, scalable manufacturing platform, deep process chemistry expertise, and established global regulatory compliance framework. AIL has adequate capacities to meet this requirement and thus this contract supports AIL to attain higher capacity utilisation and volumes without incremental capex. The intermediate will be used by the customer in the manufacturing and formulation of crop-protection products for global agricultural markets.Powered by Capital Market - Live News